Discovery & Clinical Trials
News and Publications
Discovering, developing & commercializing broad-spectrum antivirals
Dedicated to preventing and treating life- threatening viral infections
Innovation to address high unmet medical needs
Welcome to Chimerix
(NASDAQ: CMRX) Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need.
SUPPRESS Phase 3 Trial
SUPPRESS is designed to demonstrate the efficacy and safety of brincidofovir for the prevention of CMV infection versus a placebo control, as no therapy is currently approved for the prevention of CMV in HCT recipients.
May 12 2015
Chimerix to Present at UBS Global Healthcare Conference
May 11 2015
Chimerix Announces First Quarter Financial Results
May 04 2015
Chimerix to Announce First Quarter 2015 Financial Results on May 11, 2015